Tag:
Puma Biotechnology
Latest Headlines
Latest Headlines
Puma Biotech shares roaring up amid M&A meow
The cancer drug developer's shares have risen more than 50% in 2013 as the company begins late-stage development of its lead drug neratinib for patients with metastatic HER2-positive breast cancer.
Puma's Auerbach revs up PhIII plans after snagging SPA on cancer drug
Puma Biotechnology, which is swiftly moving its experimental cancer drug PB272 (neratinib) into a pivotal Phase III program, has now reached agreement with the FDA on a special protocol assessment, pushing a combo approach of the experimental treatment with Xeloda into a head-to-head showdown with Tykerb plus Xeloda for treatment-resistant, HER2 positive breast cancer.
Venture firm preps $100M fund for late-stage life sciences investments
Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.
Puma Biotech raises $138M in public offering to advance cancer drug from Pfizer
The company said on Thursday afternoon it sold more than 8.6 million shares for $16 per share, netting $129.1 million and adding to its coffers as the company readies for late-stage development of a potential breast cancer drug in-licensed from the drug giant Pfizer last year.
Cancer drug developer Puma jumps at NYSE listing
Puma Biotechnology aims to list its shares on the New York Stock Exchange as the Los Angeles-based company, which now trades over the counter, advances a drug licensed from Pfizer ($PFE) to late-stage development for women with HER2-positive breast cancer, according to an SEC filing Friday.
Ex-Pfizer cancer drug shows mixed results in mid-stage studies
Puma Biotechnology made its debut at the San Antonio Breast Cancer Symposium, presenting some positive data from mid-stage studies of the cancer drug the developer licensed from Pfizer ( $PFE ). The
Cougar founder snags Pfizer cancer drug, raises $55M and launches new biotech
The former CEO and founder of Cougar Biotechnology, Alan Auerbach, is back in the business of developing cancer drugs. In a series of maneuvers unveiled yesterday, Auerbach's Puma Biotechnology
